Sentinel Hospitalized Arterial and Venous Thrombotic Events in Patients Diagnosed in the Ambulatory Setting with COVID-19 Compared to Influenza

Noelle M. Cocoros¹; Sarah Dutcher²; John G. Connolly¹; Silvia Perez-Vilar²; Dena M. Carbonari³; Terese DeFor⁴; Djeneba Audrey Djibo⁵; Laura Harrington⁶; Laura Hou¹; Sean Hennessy³; Rebecca Hubbard³; Maria Kempner¹; Jennifer Kuntz⁷; Cheryl McMahill-Walraven⁵; Jolene Mosley¹; Pamala A. Pawloski⁴; Andrew Petrone¹; Allyson Pishko³; Meighan Rogers Driscoll¹; Claudia Steiner⁸; Yunping Zhou⁹; Vincent Lo Re III³

- 1. Harvard Pilgrim Health Care Institute
- 2. US Food and Drug Administration
- 3. University of Pennsylvania
- 4. HealthPartners Institute
- 5. CVS Health
- 6. Kaiser Permanente Washington
- 7. Kaiser Permanente Northwest
- 8. Kaiser Permanente Colorado
- 9. Humana Healthcare Research, Inc.

39th International Conference on Pharmacoepidemiology & Therapeutic Risk Management August 2023, Halifax, Canada

Disclosures

This project was supported by the U.S. Food and Drug Administration (Contract 75F40119D10037; Task Order 75F40119F19001).

The views expressed in this presentation represent those of the presenters and do not necessarily represent the official views of the U.S. FDA.

The following financial relationships relevant to this presentation existed during the conduct of the study:

Harrington: Grants from Kaiser Permanente Garfield Memorial Fund for COVID-19 related research

Hennessy: Grants from FDA, Pfizer, and Johnson; consulting for Novo Nordisk, Arbor Pharmaceuticals, the Medullary Thyroid Cancer Consortium (Novo Nordisk, AstraZeneca, GlaxoSmithKline and Eli Lilly), Biogen, Intercept Pharmaceuticals, Provention Bio, bluebird bio, Amylyx Pharmaceuticals; special government employee of the FDA

Hubbard: Grants from FDA and Merck

Lo Re: Research grants to his institution from FDA, personal consulting fees from Takeda outside this work **Pishko**: Research funding from Sanofi Genzyme Research to her institution

Background

- Case series and other analyses of hospitalized COVID-19 patients have indicated risk of **arterial** or **venous** thrombotic complications
- Our prior work on individuals initially diagnosed in the hospital setting with COVID-19 vs influenza demonstrated:
 - Increased risk of **venous** thrombotic events with COVID-19
 - Suggestion of more **arterial** thrombotic events with COVID-19
 - Increased mortality among those with an **arterial** or **venous** thrombotic event and COVID-19
- The incidence of these events among patients **diagnosed with COVID-19 vs influenza in the ambulatory** (i.e., outpatient and ED) setting is less clear

Aims

Among those with COVID-19 or 2018-19 seasonal influenza initially diagnosed in the ambulatory setting:

- Calculate 90-day incidence of inpatient arterial and venous thrombotic events
- Compare 90-day risk of inpatient **arterial** and **venous** thrombotic events
- ➢ Compare risk of death within 30 days of an event

We examined these aims in the periods before and after COVID-19 vaccine availability.

Study Design & Data Source

- Data source: FDA's Rapid Sentinel Distributed Database
 - 4 integrated health systems (electronic health records + claims)
 - 2 large national insurers (claims only)

• Study design: Retrospective cohort study

- Adults \geq 18 years
- COVID-19, influenza identified via diagnosis code or positive lab test (ambulatory setting)
- Thrombotic events identified via diagnosis codes (inpatient setting)
- Lab data: COVID-19, influenza, clinical labs (platelets, hemoglobin)
- $\circ~$ Identified pre-existing comorbidities, outpatient dispensed medications


Study Patients

To ensure influenza patients did not have COVID-19

	COVID-19 Cohort	Influenza Cohort			
Inclusion Criteria	COVID-19 diagnosis code <u>or</u> positive NAAT Period 1: April 2020 – Nov 2020 Period 2: Dec 2020 – May 2021	Influenza diagnosis code <u>or</u> positive NAAT Oct 2018 – April 2019			
	Ambulatory settings (outpatient, ED, institutional stay)				
	≥365 days of continuous enrollment at time of diagnosis				
Exclusion Criteria	Coinfection with another respiratory virus (RSV, adenovirus, parainfluenza, etc.)				
Prior arterial or venous thrombotic event increases risk for subsequent event; did not restrict to incident events					

ED, emergency department; NAAT, nucleic acid amplification test; RSV, respiratory syncytial virus

Primary Outcomes: Thromboembolic Events



Analysis

Absolute Risks	 Characteristics of COVID-19 and influenza cohorts Calculated absolute risk of thromboembolic outcomes within 90 days Stratified by COVID-19 vaccine availability Calculated absolute risk of death within 30 days of a primary outcome
COVID-19 vs. Influenza	 Compared characteristics between COVID-19 and influenza cohorts Propensity score (PS) fine stratification Weighted Cox regression, accounting for PS, adjusted for Data Partner Adjusted HRs (95% CIs) of outcomes for COVID-19 vs. influenza

Select Characteristics of Patients With COVID-19 or Influenza

Characteristic	COVID-19, Period 1 N = 272,065	Influenza N = 118,618	Standardized Diff. <u>After</u> PS Adjustment
Age in years [mean (SD)]	55.6 (17.5)	51.0 (16.5)	0.084
Female sex	55.5%	59.7%	0.005
Comorbidities (days -365, 0)			
Asthma	9.0%	11.3%	0.003
Atrial fibrillation/flutter	7.3%	4.8%	0.023
Chronic kidney disease	14.6%	10.2%	0.032
Diabetes mellitus	22.5%	17.1%	0.028
Heart failure	7.9%	4.9%	0.027
Hypertension	46.3%	38.6%	0.056
Hyperlipidemia	44.1%	37.2%	0.044
Obesity	24.3%	22.9%	0.019
Tobacco use	16.0%	15.7%	0.033
History (days -365, -1)			
Venous thromboembolism	2.2%	1.6%	0.012
Cardiovascular disease + outpatient anticoagulant	4.8%	3.2%	0.014
Positive NAAT at cohort entry	22.7%	1.8%	Not in PS model

Numbers of patients are prior to PS weighting and trimming. COVID-19 period 1: April 2020-Nov 2020, prior to vaccine availability

Risk of Inpatient Arterial Thrombotic Events, COVID-19 vs. Influenza

Cohort	No. Patients	No. Events	Absolute Risk	Site Adjusted Hazard Ratio (95% CI)	Site and PS Adjusted Hazard Ratio (95% CI)
Influenza, 2018-2019	118,618	535	0.45% (0.41-0.49%)	ref	ref
COVID-19, period 1	272,065	2,752	1.01% (0.97-1.05%)	2.09 (1.90 to 2.29)	1.53 (1.38-1.69)
COVID-19, period 2	342,103	3,629	1.06% (1.03-1.10%)	2.22 (2.03 to 2.43)	1.69 (1.53-1.86)

Risk of Death After Inpatient Arterial Thrombotic Events, COVID-19 vs. Influenza

Cohort	No. Patients with ATE	No. Deaths	Site Adjusted Hazard Ratio (95% CI)	Site and PS Adjusted Hazard Ratio (95% CI)
Influenza, 2018-2019	535	46	ref	ref
COVID-19, period 1	2,752	534	2.43 (1.79 to 3.28)	2.65 (1.88-3.73)
COVID-19, period 2	3,629	703	2.42 (1.80 to 3.27)	2.53 (1.82-3.51)

Risk of Inpatient Venous Thrombotic Events, COVID-19 vs. Influenza

Cohort	No. Patients	No. Events	Absolute Risk	Site Adjusted Hazard Ratio (95% CI)	Site and PS Adjusted Hazard Ratio (95% CI)
Influenza, 2018-2019	118,618	219	0.18% (0.16-0.21%)	ref	ref
COVID-19, period 1	272,065	1,994	0.73% (0.70-0.77%)	3.74 (3.25 to 4.30)	2.86 (2.46-3.32)
COVID-19, period 2	342,103	2,994	0.88% (0.84-0.91%)	4.55 (3.96 to 5.22)	3.56 (3.08-4.12)

Risk of Death After Inpatient Venous Thrombotic Events, COVID-19 vs. Influenza

Cohort	No. Patients with VTE	No. Deaths	Site Adjusted Hazard Ratio (95% CI)	Site and PS Adjusted Hazard Ratio (95% CI)
Influenza, 2018-2019	219	15	ref	ref
COVID-19, period 1	1,994	316	2.34 (1.39 to 3.93)	2.36 (1.34-4.18)
COVID-19, period 2	2,994	527	2.68 (1.61 to 4.49)	2.58 (1.48-4.50)

Study Limitations & Considerations

	 ICD-10 diagnoses for thromboembolic events not validated
Misclassification	Clinicians may have been more likely to diagnose events in COVID-19
	 Under-captured outcomes for COVID-19 (e.g., out-of-hospital death)
	 Only included commercially insured individuals
Generalizability	One influenza season
	 Medically attended COVID-19 and influenza
	 Small proportion of cohorts identified via positive laboratory test
Data Availability	 Vaccination status not identified due to incomplete capture
	 Incomplete race, Hispanic ethnicity data; not included in analyses
	 Inpatient medications unknown (e.g., prophylactic anticoagulation)

Conclusions

- Ambulatory patients diagnosed with COVID-19 both before and after vaccine availability had a higher risk of inpatient **arterial** and **venous** thrombotic events than patients with 2018-19 influenza
- After an inpatient **arterial** or **venous** thrombotic event, the risk of death was 2-3 times higher for patients with COVID-19 versus influenza

Sentinel

Sentinel Operations Center Da

- John Connolly
- Laura Hou
- Meighan Rogers Driscoll
- Maria Kempner
- Jolene Mosley
- Andrew Petrone
- Jenice Ko
- Emma Hoffman

University of Pennsylvania

- Dena M. Carbonari
- Sean Hennessy
- Rebecca Hubbard
- Allyson M. Pishko
- Vincent Lo Re, III

Data Partners

- CVS Health: Cheryl Walraven, Audrey Djibo, Carla Brannan, Annemarie Kline
- HealthPartners: Pamala Pawloski, Terese DeFor, Jacob Zillhardt, Heidi Bailly, Dianne Eggen, Laurie VanArman
- Humana: Thomas Harkins, Yunping Zhou, Vinit Nair
- Kaiser Permanente Colorado: Claudia Steiner, Karen Glenn, Mahesh Maiyani, Erica Morse
- Kaiser Permanente Northwest: Jennifer Kuntz, Catherine Cleveland, Daniel Vaughn, Celeste Machen
- Kaiser Permanente Washington: Laura Harrington, Monica Fujii, Ron Johnson, Vina Graham

US Food & Drug Administration

- Sarah K. Dutcher
- Silvia Perez-Vilar